Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
LUMOS PHARMA, INC. (NLNK) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Investor presentation, Quarterly results
Docs: "Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update",
"Second Quarter 2023 Financial Results"
05/03/2023 8-K Investor presentation, Quarterly results
Docs: "Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates",
"First Quarter 2023 Financial Results"
03/01/2023 8-K Investor presentation, Quarterly results
Docs: "Lumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development Updates",
"Full Year 2022 Financial Results"
08/09/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
03/10/2022 8-K Investor presentation, Quarterly results
Docs: "Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials",
"Full Year 2021 Financial Results"
11/03/2021 8-K Investor presentation, Quarterly results
Docs: "Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates",
"Third Quarter 2021 November 3, 2021 2 Forward Looking Statements This"
08/05/2021 8-K Investor presentation, Quarterly results
Docs: "Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates",
"Second Quarter 2021 Financial Results Presentation"
05/05/2021 8-K Quarterly results
03/09/2021 8-K Quarterly results
11/10/2020 8-K Investor presentation, Quarterly results
Docs: "Lumos Pharma Announces the Initiation of Phase 2b OraGrowtH210 Trial and Reports Third Quarter 2020 Financial Results • Lumos Pharma has initiated Phase 2b OraGrowtH210 Trial evaluating oral LUM-201 in pediatric growth hormone deficiency patients with data read-out anticipated mid-year 2022",
"Third Quarter 2020 Financial Results Presentation"
08/13/2020 8-K Quarterly results
05/28/2020 8-K Investor presentation, Quarterly results
Docs: "Lumos Pharma Reports First Quarter 2020 Results and Provides Update on Clinical and Corporate Activities – Lumos Pharma expects to initiate its Phase 2b LUM-201 trial in Pediatric Growth Hormone Deficiency prior to the end of 2020 – Additional non-dilutive funds expected from anticipated monetization of priority review voucher – Cash on hand expected to fund current operations through Phase 2b trial read-out",
"First Quarter 2020 Financial Results Presentation"
09/30/2019 8-K Quarterly results
05/08/2019 8-K Investor presentation, Quarterly results
Docs: "NewLink Genetics Reports First Quarter 2019 Financial Results and Provides Clinical Activities Update - Management to host conference call today at 4:30 p.m. ET",
"First Quarter 2019 Financial Results Presentation"
02/27/2019 8-K Quarterly results
11/01/2018 8-K Investor presentation, Quarterly results
Docs: "NewLink Genetics Reports Third Quarter 2018 Financial Results and Announces Abstracts to Be Presented at Upcoming Medical Meetings Management to Host Conference Call Today at 4:30 p.m. ET",
"Third Quarter 2018 Financial Results Presentation"
07/31/2018 8-K Investor presentation, Quarterly results
Docs: "NewLink Genetics Announces Clinical Plan, Reports Second Quarter 2018 Financial Results and Revises Cash Guidance Management to Host Conference Call Today at 4:30 p.m. ET",
"Second Quarter 2018 Financial Results Presentation"
05/03/2018 8-K Investor presentation, Quarterly results
Docs: "NewLink Genetics Reports First Quarter 2018 Financial Results Management to Host Conference Call Today at 4:30 p.m. ET",
"First Quarter 2018 Financial Results Presentation"
04/16/2018 8-K Investor presentation
Docs: "NewLink Genetics Announces Initial Phase 1 Data with Indoximod Plus Radiation and Chemotherapy for Pediatric Patients with Diffuse Intrinsic Pontine Glioma Presented During AACR Plenary Early data indicate indoximod has clinical activity when used in combination therapies beyond PD-1 inhibition",
"DIPG Presentation Slide Deck"
03/01/2018 8-K Investor presentation
Docs: "NewLink Genetics Reports Fourth Quarter, Year-End 2017 Financial Results and Provides Update for Indoximod Programs - Management to Host Conference Call Today at 4:30 p.m. ET",
"Fourth Quarter and Year-End 2017 Financial Results Presentation"
01/08/2018 8-K Investor presentation
Docs: "NewLink Genetics Outlines 2018 Business Priorities to Support Phase 3 Pivotal Trial of Indoximod Plus PD-1 Inhibitors NewLink Genetics updates financial and clinical guidance",
"J.P. Morgan Healthcare Conference Presentation"
11/02/2017 8-K Investor presentation, Quarterly results
Docs: "NewLink Genetics Reports Third Quarter 2017 Financial Results and Updates Indoximod Program - Management to Host Conference Call Today at 8:30 a.m. ET",
"Third Quarter 2017 Financial Results Presentation"
07/28/2017 8-K Form 8-K - Current report:
05/04/2017 8-K Form 8-K - Current report
02/28/2017 8-K Form 8-K - Current report
11/01/2016 8-K Form 8-K - Current report
07/29/2016 8-K Form 8-K - Current report
04/29/2016 8-K Form 8-K - Current report
02/29/2016 8-K Form 8-K - Current report
09/26/2013 8-K Investor presentation
Docs: "NewLink Genetics Presentation Materials"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy